Skip to main content

Table 2 Number of cycles of weekly gemcitabine with respect to age in stage III NSCLC

From: Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer

 

Age < 70

 

Age ≥ 70

 

Total

 

1

1

(<1%)

0

 

1

(<1%)

2

7

(3%)

3

(3%)

10

(3%)

3

9

(4%)

7

(8%)

16

(5%)

4

13

(6%)

11

(12%)

24

(8%)

5

188

(84%)

71

(76%)

259

(84%)

  1. From 8 patients the weekly gemcitabine dosage was not specified.